In PDX models bearing the ESR1 Y537S mutant, palazestrant inhibits tumor growth at a 3 mg/kg dose and enhances tumor shrinkage at higher doses or combined with CDK4/6 inhibitors. Here, ESR1 is linked to neoplasm.